Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Sarepta Therapeutics (SRPT) Other financing activities (2018 - 2025)

Sarepta Therapeutics has reported Other financing activities over the past 7 years, most recently at $110000.0 for Q4 2025.

For Q4 2025, Other financing activities changed N/A year-over-year to $110000.0; the TTM value through Dec 2025 reached $664000.0, up 19.86%, while the annual FY2025 figure was $2.4 million, N/A changed from the prior year.
Other financing activities for Q4 2025 was $110000.0 at Sarepta Therapeutics, down from $554000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.4 million in Q2 2021 and troughed at $110000.0 in Q4 2025.
A 3-year average of $698666.7 and a median of $554000.0 in 2022 define the central range for Other financing activities.